Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by Sensanomeon Jan 23, 2020 12:59pm

69 Views

Post# 30589499

ON A SIDE NOTE....MRS.V MAYBE AN OPPORTUNITY FOR SOME!!

https://finance.yahoo.com/news/mission-ready-outperforms-q4-2019-134935024.html

Managment just bought a 0.15

Filed 2020-01-06 13:31 Tx date 2020-01-03	$MRS Mission Ready Solutions Inc.	Raczykowski, Daniel Gene 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Common Shares 16 - Acquisition or disposition under a prospectus exemption	$330,625.05 +2,204,167 vol $0.15 each	12,730,483